S&P 500
(0.22%) 5 319.83 points
Dow Jones
(0.15%) 39 868 points
Nasdaq
(0.16%) 16 822 points
Oil
(-0.93%) $79.06
Gas
(-2.58%) $2.68
Gold
(-0.41%) $2 428.60
Silver
(-0.47%) $32.28
Platinum
(0.08%) $1 064.60
USD/EUR
(0.05%) $0.921
USD/NOK
(-0.29%) $10.67
USD/GBP
(-0.06%) $0.786
USD/RUB
(-0.40%) $90.31

Realtime updates for BridgeBio Pharma Inc [BBIO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return 0.65%
SELL
34.15%
return 10.72%
Last Updated21 May 2024 @ 15:41

-0.78% $ 29.29

BUY 6131 min ago

@ $30.66

Issued: 17 May 2024 @ 09:30


Return: -4.47%


Previous signal: Apr 8 - 09:34


Previous signal: Sell


Return: 6.72 %

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 15:41):
Profile picture for BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development...

Stats
Today's Volume 1.18M
Average Volume 1.64M
Market Cap 5.48B
EPS $0 ( 2024-05-02 )
Next earnings date ( $-0.890 ) 2024-06-21
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -9.07
ATR14 $0.0400 (0.14%)
Insider Trading
Date Person Action Amount type
2024-05-16 Kumar Neil Buy 60 667 Common Stock
2024-05-16 Kumar Neil Sell 30 748 Common Stock
2024-05-16 Kumar Neil Sell 33 544 Restricted Stock Units
2024-05-16 Kumar Neil Sell 19 599 Restricted Stock Units
2024-05-16 Kumar Neil Sell 2 394 Restricted Stock Units
INSIDER POWER
-22.12
Last 100 transactions
Buy: 1 449 737 | Sell: 2 584 140

Volume Correlation

Long: 0.29 (neutral)
Short: 0.80 (moderate)
Signal:(60.145) Neutral

BridgeBio Pharma Inc Correlation

10 Most Positive Correlations
RRGB0.929
SPTN0.924
NARI0.924
AMPH0.923
LPSN0.92
BMBL0.92
ASLE0.917
BGFV0.915
ACON0.915
BNRG0.915
10 Most Negative Correlations
ASMB-0.922
ESTA-0.919
KINS-0.914
JVA-0.905
NTRA-0.905
CDRO-0.9
MTEK-0.896
EDAP-0.894
RNA-0.893
DXJS-0.891

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BridgeBio Pharma Inc Correlation - Currency/Commodity

The country flag 0.84
( strong )
The country flag 0.76
( moderate )
The country flag 0.00
( neutral )
The country flag 0.29
( neutral )
The country flag 0.52
( weak )
The country flag -0.17
( neutral )

BridgeBio Pharma Inc Financials

Annual 2023
Revenue: $9.30M
Gross Profit: $6.86M (73.71 %)
EPS: $-3.95
FY 2023
Revenue: $9.30M
Gross Profit: $6.86M (73.71 %)
EPS: $-3.95
FY 2022
Revenue: $77.65M
Gross Profit: $74.21M (95.58 %)
EPS: $-3.35
FY 2021
Revenue: $69.72M
Gross Profit: $66.60M (95.53 %)
EPS: $-4.77

Financial Reports:

No articles found.

BridgeBio Pharma Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators